Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Janet Pope Janetbirdope
6 days 10 hours ago
Controversial
#Rheumatoid #arthritis disease activity
May not affect #ILD
BUT affects #mortality
level evidence +/-
PHillippe Dieude said
#Rx from RCTs
#IS
Ex #rituximab
#antifibrotics
#nintedanib
#nerandomilast
HOw to Treat RA-ILD June 5
#EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Nelly ZIADE 🍀 Nellziade
6 days 10 hours ago
Which b/tsDMARDs are NOT effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/hqfLAYeri3
sheila RHEUMarampa
6 days 10 hours ago
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
Dr. John Cush RheumNow
6 days 11 hours ago
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Nelly ZIADE 🍀 Nellziade
6 days 11 hours ago
Which b/tsDMARDs are effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/8mj24lAOTk
sheila RHEUMarampa
6 days 11 hours ago
What b/ts DMARDs are effective and not effective in axSpA?
Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA.
@RheumNow #EULAR2026 https://t.co/5udGPB1Hrr
Nelly ZIADE 🍀 Nellziade
6 days 11 hours ago
What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis?
👉 DAPSA44
✔️Good construct validity
✔️ High discriminatory capacity
From the ASAS-Sparadise study
#EULAR2026
@RheumNow https://t.co/Jbdvpn95jE
Janet Pope Janetbirdope
6 days 11 hours ago
#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming
➡️esp if multi drug failure already
By Hector Chinoy #WIN #IIM June5
Excellent #CAR-T review
should re think of
Total immune reset in many #SARD PTS is unlikely
EULAR2026 @RheumNow https://t.co/eqKzxzqa0z
Bella Mehta bella_mehta
6 days 11 hours ago
Using AI to integrate EHR, SDOH , psychological data - can help finding psychosocial risk factors.
Complex cases can be diagnosed using solutions (iceberg health) like this. #EULAR2026 @rheumnow https://t.co/t4keRbpkrx
sheila RHEUMarampa
6 days 11 hours ago
Not just ticking boxes!
Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA
What’s new?
Providing a stem so criteria will be applied only if w/SpA dx, not just imaging
MRI:active inflamm + structural lesions
Some SpA features omitted
@RheumNow #EULAR2026 https://t.co/NCV0EFvjYa
Janet Pope Janetbirdope
6 days 11 hours ago
Can we have an effective, comprehensive score for
#SLE #arthritis?
#SLEDAI has a problem
SJC>2 scores dames as ex #SJC=12
Meet
#LAMBDA
An attempt to improve a true positive #MSK OUTCOME in #lupus
Needs validation esp in pts over time
#EULAR2026 @RheumNow #POS1072
@eular_org https://t.co/fr0xuVqFnM
Antoni Chan MD (Prof) synovialjoints
6 days 11 hours ago
Large French nationwide cohort (n=56,591 SpA patients) showed that >6 months/year of targeted therapy exposure was associated with reduced overall cancer risk (wHR 0.86), especially for haematological malignancies (wHR 0.65). Reassuring long-term safety signal. Abstr OP0238
